To create a clinical prediction index that aids in the diagnosis of picornavirus respiratory infections, we analyzed patients from 5 clinical trials designed to evaluate the efficacy of an antiviral treatment for respiratory infections. Logistic regression was used to determine which baseline symptoms and patient characteristics best predicted picornavirus infection. Parameter estimates were then used to create a predictive index for estimating the probability of picornavirus infection on the basis of cold symptoms. The presence at baseline of rhinorrhea (odds ratio Noninfluenza-virus respiratory infections, also known as colds or "common respiratory illnesses," are frequent conditions, with ∼500 million episodes occurring each year in the United States [1] . It is estimated that children experience 6-8 of these episodes per year, whereas adults experience 2-4 episodes per year [2] [3] [4] . The large number of annual episodes leads to substantial use of medical resources and absence from school and work [1, 5] . Noninfluenza-virus respiratory infection is characterized by a constellation of symptoms, including congestion, rhinorrhea, and sore throat. Other respiratory conditions, such as asthma and chronic obstructive pulmonary disease, are frequently exacerbated by noninfluenza-virus respiratory infection, thus increasing the potential of hospitalization for these conditions [6] [7] [8] [9] [10] [11] .
Noninfluenza-virus respiratory infections, also known as colds or "common respiratory illnesses," are frequent conditions, with ∼500 million episodes occurring each year in the United States [1] . It is estimated that children experience 6-8 of these episodes per year, whereas adults experience 2-4 episodes per year [2] [3] [4] . The large number of annual episodes leads to substantial use of medical resources and absence from school and work [1, 5] . Noninfluenza-virus respiratory infection is characterized by a constellation of symptoms, including congestion, rhinorrhea, and sore throat. Other respiratory conditions, such as asthma and chronic obstructive pulmonary disease, are frequently exacerbated by noninfluenza-virus respiratory infection, thus increasing the potential of hospitalization for these conditions [6] [7] [8] [9] [10] [11] .
Picornaviruses, mainly rhinoviruses, cause ∼50% of episodes of noninfluenza-virus respiratory infection annually with a significantly higher proportion during peak seasons [3, 4, 12] . Current therapies for picornavirus infection consist primarily of over-the-counter medications that possess no antiviral effects, limited effectiveness in reducing symptoms, and significant potential for adverse events, which may lead to further resource use. However, specific antiviral therapies are being developed that are capable of treating the most common pathogen associated with noninfluenza virus respiratory infection, the picornavirus [13] [14] [15] .
Previously, the clinical distinction between picornavirus infections and nonpicornavirus infections has not been necessary. The potential availability of these antipicornavirus therapies, however, has made this clinical distinction necessary in order to facilitate the appropriate delivery of these therapies to those patients most likely to benefit from them. Rapid, reliable, and accessible laboratory confirmation of picornavirus infection would be ideal, but such confirmation is currently not available and will not be available in the near future. Clinical predictors of influenza virus infection have been developed and validated [16, 17] . Rapid tests for the presence of influenza virus are in use, but their value at the individual level has been questioned because of issues of sensitivity and cost [18] . Similarly, the ability to identify picornavirus infections on the basis of an array of signs and symptoms would be useful to ensure the appropriate and effective use of antipicornavirus therapies. Therefore, the objective of this study was to create a clinical prediction index to aid in the diagnosis of picornavirus respiratory infections. Here we present results for such an index, which was developed using enrollment data from clinical trials.
SUBJECTS AND METHODS

Patient eligibility.
We analyzed patients with self-diagnosed colds who participated in 5 clinical trials designed to evaluate the efficacy of a tablet formulation of pleconaril in the treatment of viral respiratory infections in adults and adolescents [15] . Study participants were selected from patients presenting at ambulatory and emergency medical clinics with a symptom complex consistent with viral respiratory tract illness. To be eligible, study participants were required to have various combinations of respiratory symptoms (i.e., nasal congestion, rhinorrhea, cough, or sore throat) and systemic symptoms (i.e., malaise or myalgia) of the cold. These symptoms correspond to those previously assessed in reports detailing the clinical course of naturally acquired colds [12, 19] . Inclusion and exclusion criteria differed slightly across the 5 trials (table 1) . Data collection. Data regarding the patients' symptoms were collected at baseline before randomization to any treatment. Presence of the following symptoms at baseline was recorded: malaise, myalgia, nasal congestion, rhinorrhea, cough, sore throat, and fever. Other than fever, all symptoms were rated on a 4-point scale, as follows: absent, 0; mild, 1; moderate, 2; and severe, 3. For analytical purposes, "moderate" and "severe" ratings indicated the presence of a symptom, whereas "absent" and "mild" ratings indicated the absence of a symptom. Definitions of the presence and absence of each symptom are listed in table 2.
The presence of picornaviruses was assayed by RT-PCR and culture. Immediately before receiving the first dose of blinded study medication, all patients were instructed to expel nasal mucus into plastic wrap or a bag. The nasal mucus was then swabbed, placed in transport medium, and sent to a central virology laboratory for RT-PCR detection of picornavirus RNA and for culture. All nasal mucus samples from a given patient were analyzed in the same assay, and all were tested by the automated TaqMan (Applied Biosystems) system to determine whether the patient was picornavirus-infected. If a baseline nasal mucus sample tested negative for picornavirus by RT-PCR, the sample was then tested by a manual enzyme-linked oligonucleotidesorbent assay (ELOSA). RT-PCR procedures have been described elsewhere [12] .
Analysis. Eligible subjects from the 5 clinical trials were randomly divided into 2 groups, an analysis group (60%) and a holdout group (40%). Data from the analysis group were used to estimate the parameters for deriving the clinical prediction index. Data from the holdout group were used to validate the clinical prediction model.
Univariate and multivariate analyses were conducted to compare each patient's symptom and demographic profile with that of a patient with laboratory-confirmed picornavirus infection. Demographic variables investigated were age, sex, and ethnicity. Picornavirus infection was modeled by means of logistic regression to determine which baseline symptoms and patient characteristics best predicted picornavirus infection. The best set of predictors was determined by an iterative process encompassing both univariate and multivariate analyses of all variables, including assessments of confounding.
The discriminating ability of the model was assessed using measurements of sensitivity and specificity. A decision rule was applied to the predicted probabilities by use of a cutoff value of 0.5 to assess these measurements. Measurements of sensitivity and specificity are usually biased because the classified observations are used to estimate the parameters of the model. The entire holdout group was classified according to the parameter estimates obtained from the analysis group. Because data from members of the holdout group were not used to estimate the parameters, the model was completely uninfluenced by any of the held out observations, which later served to validate the model obtained using data from the analysis group. After validation, the parameter estimates from the model were used to create a predictive index. The index was the summed score of symptoms and signs weighted by their predictive value. This index represents the risk of picornavirus infection as identified by the predictive model.
RESULTS
A total of 4196 clinical trial patients met the criteria for inclusion in the analysis (table 3) . Case patients were predominantly female (69%), white (80%), and !40 years of age (65%). The most common symptom was rhinorrhea (in 81% of patients), followed by malaise (in 66%), nasal congestion (in 63%), and sore throat (in 49%). Cough or myalgia was present in !40% of the patients, and fever was present in only 4% of the patients. Approximately 53% of the patients tested positive for picornavirus. Fewer than 1.5% of the patients were enrolled outside of the August-November time period. Of the patients enrolled during the August-November time period, the picornavirus infection rate ranged from a high of 63% in September to a low of 44% in November. Analysis group. In the analysis group, the most common symptoms among patients with laboratory-confirmed picornavirus infection were rhinorrhea (in 89%), nasal congestion (in 71%), malaise (in 63%), and sore throat (in 52%) (table 4). Patients without laboratory-confirmed picornavirus infection also frequently presented with rhinorrhea (71%) and malaise (70%). Patients with picornavirus infection were more likely than patients without picornavirus infection to present with rhinorrhea ( ), nasal congestion ( ), and P ! .0001 P ! .0001 sore throat ( ), and less likely to present with myalgia P p .005 ( ), malaise ( ), and fever ( ). Fur-P ! .0001 P p .0004 P ! .0001 thermore, patients with picornavirus infections were more likely to be white ( ) and !40 years of age ( ) P ! .0001 P p .002 than were patients without picornavirus infection.
Predictive modeling. Multivariate modeling of the data from members of the analysis group identified 7 baseline symptoms and characteristics as significant predictors of picornavirus infection ( ). P p .002
The ability of this model to accurately identify patients with picornavirus infection was assessed using measurements of sensitivity and specificity. The model correctly classified 999 of 1318 picornavirus infections, for a sensitivity of 75.8%. The model correctly classified 578 of 1203 nonpicornavirus infections, for a specificity of 48.0%. Overall, the model correctly classified 62.6% of the patients. The positive predictive value of the model was 61.5%, and the negative predictive value was 64.4%.
The predictive model was validated using data for the holdout group. Because data for members of the holdout group were not used to estimate the parameters of the prediction model, the model was not influenced by any of the held out observations. The model correctly classified 691 of 904 picornavirus infections and 360 of 771 nonpicornavirus infections in members of the holdout group, for a sensitivity of 76.4% and a specificity of 46.7%. Overall, the model correctly classified 62.7% of the members of the holdout group, matching the rate of correct classifications obtained with the analysis group.
Predictive index. Because the predictive model was used to obtain accurate classifications of picornavirus infections, the parameter estimates from the model can be used to construct an index reflecting the probability of picornavirus infection. To simplify its clinical use, the index was based solely on the presence or absence of symptoms. The index was further simplified by multiplying the parameter estimates by a common factor (4) and rounding the product to the nearest whole number (table 6). These whole numbers represent the weights that correspond to the patient's symptoms, which can then be summed to form a predictive index (table 7) . For example, a patient with rhinorrhea, fever, and nasal congestion would have an index score of 4. A comparison of this index score with figure 1 suggests that this patient has nearly a 50% probability of having picornavirus infection.
DISCUSSION
Viral respiratory infections are the most common of the acute illnesses experienced by persons of all ages, and they are a common cause of outpatient medical visits [2] [3] [4] . Many of these visits are related to rhinovirus infections or their complications [6, 7, 9] . However, historically, the identification of the etiology of noninfluenza-virus respiratory infections was not necessary because of the unavailability of specific therapy, which necessitated the use of symptomatic treatments, such as deconges- Previously, clinical predictors for influenza virus illness have been developed using data from surveillance studies as well as information from clinical trials. Here, too, the need for such predictors was based on the availability of new, specific antiviral drugs for the treatment of influenza virus infection. For picornaviruses, the identification of etiologic agents is rarely performed even as a part of surveillance. Thus, for this study, data were used from a series of large clinical trials of the antirhinovirus compound pleconaril, which allowed for a correlation of clinical characteristics with picornavirus infection, as detected by RT-PCR and culture of nasal mucus samples. These studies did differ somewhat in their inclusion and exclusion criteria, which produced the heterogeneity required to identify the factors that predicted picornavirus positivity. In particular, patients with fever were excluded from the later trials, thereby increasing the likelihood that participants would have test results positive for picornavirus infection, the most common cause of the cold.
The current study demonstrates that rhinorrhea, nasal congestion, and sore throat are positively associated with picornavirus infection, whereas myalgia and fever are negatively associated with picornavirus infection. Previous research conducted by Gwaltney et al. [4] drew somewhat similar conclusions. Rhinorrhea and congestion were positively associated with test results positive for rhinovirus, but sore throat was negatively associated with such results. This opposite finding with regard to sore throat has several possible explanations, including differences in assay techniques and their focus on rhinovirus infections rather than picornavirus infections. The most likely explanation, however, relates to the timing of the differences between rhinovirus-positive and rhinovirus-negative infections. In the study of Gwaltney et al. [4] , the frequency of symptoms and signs associated with rhinovirus-positive colds was compared to that for rhinovirus-negative colds over the entire course of the illness, and did not solely focus on the symptom complex present at the time of diagnosis. Whether sore throats are more common in the early stages of rhinoviruspositive infections compared with rhinovirus-negative infections is not ascertainable from the findings of that study [4] ; however, a more recent study conducted by Arruda et al. [12] has identified sore throat as one of the earliest symptoms. The research of Gwaltney et al. [4] also indicated that cough is more frequently associated with rhinovirus infections. Although this was true over the time course of the illness, cough was not a symptom frequently experienced at the onset of illness [19] .
The model generated from the clinical trial symptom data was used to create a predictive index. Because this index was generated from a relatively homogeneous study population, its application to everyday practice and various patient populations is speculative. More specifically, because the predictive index was based on data from primarily young, white adults, it may not be useful for children, the elderly, or other ethnic groups. In addition, inclusion of information about specific subgroups of patients, who may need to be treated at lower thresholds because of the possibility of complications, would further enhance the usefulness of the index. These subgroups may include, but are not limited to, patients with chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease [20] [21] [22] . Because these questions remain unanswered, use of the index score by clinicians currently must be treated as developmental.
The emergence of new technologies for use in clinical practice requires novel approaches to medical decision making. Most recently, the introduction of new anti-influenza virus drugs necessitated the identification of symptomatic predictors of cases of illness for which cell culture results would be positive. That predictive model, derived (as in this study) from clinical trial data, has since been validated in a more representative surveillance population [17] . Such validation will also need to be performed for the picornavirus-infection index. In the interim, this index can aid medical professionals who may be confronted with a new need to decide when to treat persons presenting with early symptoms of the cold.
